Welcome to Pharmacology at CWRU
Our mission is to discover specific mechanisms that control physiological processes at the cellular and molecular level. Our basic science approach is the best framework for rational drug design, and our research offers hope for defeating some of humanity's most devastating diseases--breast cancer, AIDS, blindness, hypertension, Alzheimer's, and diabetes.
The mission of our Department encompasses research and education in molecular, cellular, and clinical pharmacology. We actively participate in five specialized research centers associated primarily with the Department of Pharmacology and we are committed to supporting the community of faculty, postdoctoral fellows, and graduate students in support of today's research for tomorrow's cures.
Posted on 4/18/2013
Andrea Boyd-Tressler Wins at the BGSS
Andrea wins a prize for her poster presented at the Biomedical Graduate Student Symposium. The poster was entitled: "Pro-apoptotic agents induce ATP release from leukemia/ lymphoma tumor cells via pannexin-1 dependent and pannexin-1 independent mechanism".
Congratulations on a job well done!
Posted on 5/13/2013
Krzysztof Palczewski Receives Pretigious Award!
Dr. Krzysztof Palczewski receives the 2013 Faculty Research Award for excellence in research. President Barbara Snyder, Dean Pam Davis, and Provost and Executive Vice President, William A. "Bud" Baeslack III, award Kris with this pretigious honor! His lab group and faculty members gathered to congratulate him.
Posted on 5/12/2013
Will Johnson, a graduate student working in the laboratories of Amy Wilson-Delfosse and John Mieyal is awarded a Parkinson's Disease Foundation Student Fellowship. Good Job Will!
Posted on 4/29/2013
Gary Landreth, a trainer in Pharmacology, receives license for Alzheimer's treatment
CWRU research spinoff ReXceptor receives exclusive license for Alzheimer’s disease treatment
Case Western Reserve’s Technology Transfer Office has granted an exclusive license of a novel Alzheimer’s disease treatment strategy to spinoff company ReXceptor Inc., which plans to initiate early-stage human clinical trials of the medication within the next few months. Professor Gary Landreth and his then-graduate student, Paige Cramer, co-founded ReXceptor after discovering that bexarotene reversed AD symptoms in mice within 72 hours of a single dose of treatment.
Learn more here: http://cwru-daily.com/news/cwru-research-spinoff-rexceptor-receives-exclusive-license-for-alzheimers-disease-treatment-2/
Posted on 4/29/2013